GlaxoSmithKline Pharmaceuticals Limited submitted a regulatory filing to BSE Limited and The National Stock Exchange of India Limited pursuant to Regulation 30 read with Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The filing contains an investor presentation that was shared during Analysts/Investors Call and uploaded on the company website.

Management Overview

  • Mr. Bhushan Akshikar has been Managing Director of GSK India since Q3 2022, bringing over 15 years of leadership experience within GSK across India, Middle East, Russia CIS & Africa region
  • Prior to GSK, Bhushan spent 15 years with Johnson & Johnson in local and regional positions in India, S. Korea and Belgium
  • Mr. Ronojit Biswas has been Chief Financial Officer since April 2026, bringing over 25 years of experience across global finance roles in India, Vietnam, Singapore, Brazil and UK
  • Prior to this role, Ronojit served as Senior Finance Director – Global Product Strategy for General Medicines Therapy Area and was Regional Controller (International) and CFO for GSK's Brazil and Vietnam businesses

Market Performance Q1 FY27

  • Indian Pharmaceutical Market (IPM) grew at 13.5% in Q1 FY27
  • GSK grew faster than its representative market
  • Key brands remained competitive in the market

Business Segment Performance

General Medicines:

  • Market share improved with +0.6% value market share gain
  • Value EI (Effective Index) at 101
  • Key brand performance:
  • Augmentin: Val EI 105, Val MS 22% (+1.0% gain), Value Growth 12.80%
  • Calpol: Val EI 106, Val MS 31.2% (+1.6% gain), Value Growth 8.10%
  • T-Bact: Val EI 105, Val MS 57.5% (+2.6% gain), Value Growth 17.90%
  • Ceftum: Val EI 101, Val MS 32.7% (+0.2% gain), Value Growth 7.60%
  • Key Promoted Brands: Val EI 100, Val MS 23.4% (0% change), Value Growth 11.30%

Vaccines:

  • Established Vaccines continues to lead overall vaccines market with 26.1% Value Market Share
  • Unit EI 95 & Val EI 93
  • Building adult immunization category through Shingrix
  • Driving 2026 growth through CVMD opportunity
  • 2.6k prescribers for Shingrix, representing 39% YoY growth

Respiratory Segment:

  • Building equity in Respiratory Segment
  • Monthly units maintained >19% versus average units post-Loss of Exclusive (LoE) in April 2025
  • 3,500+ severe asthma new patient uptake
  • 7.7 million+ touchpoints

Commercial Operations

  • Improving Share of Voice (SoV) and elevating customer experience through digital innovation
  • 360,000+ unique Healthcare Professionals (HCPs) reached through both face-to-face and digital channels

Financial Highlights Q1 FY26-27 (Standalone)

Revenue Performance:

  • Revenue: ₹924 crore
  • Growth: +15% year-over-year
  • Sales growth driven by execution excellence, portfolio transformation strategy, and favorable base effect compared to previous year

Profitability Metrics:

  • PAT: ₹253 crore
  • PAT Margin: 27.6% (+200 bps year-over-year)
  • PAT Growth: +24% year-over-year
  • EBITDA: ₹293 crore
  • EBITDA Margin: 31.7% (+50 bps year-over-year)
  • EBITDA Growth: +17% year-over-year
  • EPS: 14.95 (+24% year-over-year)

Portfolio Transformation:

  • Innovation portfolio accounts for 7% of total sales (previous year: 4%)
  • Innovation portfolio driving one-fourth of headline growth
  • Innovation defined as: Oncology (Jemperli + Zejula) + New Respiratory (Nucala + Trelegy) + Adult Vaccines (Shingrix)
  • Building momentum with Oncology launches & New respiratory products
  • General medicines growth led by brands Augmentin, Ceftum and T-Bact
  • Pediatric Vaccines continued leadership in self-pay private pediatric market
  • Shingrix delivered 65% growth driven by HCPs and HCOs engagement to shape the category

Margin Analysis:

  • EBITDA improvement driven by gross margin improvement
  • Gross margin improved +150 bps due to pricing and favorable mix, offset by higher EGOL and other costs
  • SG&A as percentage of sales higher by 1%, mainly driven by investments in core brands & new products
  • PAT improvement due to consistent gross margin improvement and one-off dividend from Biddle Sawyer Limited (100% subsidiary)
  • Sustained focus to strengthen and optimize the balance sheet

Competitive Performance

  • Consistent competitive performance and profitability improvement with portfolio transformation
  • Market share of Key promoted brands in its representative market maintained
  • Key promoted brands include: Augmentin, Calpol, Ceftum, T-bact, CCM, Cobadex CZS, Eltroxin, Tenovate, Neosporin, Supacef